Reguero J R, Cubero G I, Batalla A, Alvarez V, Hevia S, Cortina A, Coto E
Department of Cardiology, Instituto Reina Sofia de Investigación Nefrológica, Hospital Central de Asturias, Oviedo, Spain.
Cardiology. 1998 Dec;90(3):231-5. doi: 10.1159/000006849.
Genetic studies have identified polymorphisms at the apolipoprotein (Apo) A1 gene associated with HDL cholesterol and apolipoprotein levels, and a relationship between the severity of coronary artery disease and polymorphisms at the 5'-end of Apo A1 has been also reported. This study was designed to examine the relationship between polymorphism at the Apo A1 gene and the risk of early coronary artery disease. Furthermore, the association of the polymorphism with the classical risk factors was analyzed. A total of 176 male patients (mean age 43 +/- 5 years) diagnosed as having unstable angina (53 cases) or myocardial infarction (123 cases) were prospectively evaluated. Data referring to hypertension, diabetes and tobacco consumption were recorded. The levels of total cholesterol, HDL cholesterol, Apo A1 and B and triglycerides were determined. DNA was obtained from the 176 patients and from 200 controls. In order to determine the Apo A1 genotypes at two polymorphic sites (G/A at -75 bp, and C/T at +83 bp), DNA was PCR amplified and digested with MspI. The frequency of carriers of the rare allele at the -75 bp site (M1-) was 0.34 in cases and 0.24 in controls (p < 0.05). The frequencies of the M1- allele among patients with angina and myocardial infarction were 0.43 (p = 0.009, angina vs. controls) and 0.30, respectively. No significant association between this polymorphism and other cardiovascular risk factors was found. No difference in the frequencies for carriers of the rare allele at the +83-bp polymorphism (M2) was observed among patients with angina (0.08 vs. 0.07) or myocardial infarction (0.04 vs. 0.07), and no association between this polymorphism and tobacco, hypertension and diabetes was noted. Patients carrying the rare M2- allele had a lower concentration of total cholesterol compared to those without this allele (183 +/- 29 vs. 223 +/- 54, p < 0.04) and HDL cholesterol was also lower among patients carrying the M2- (26 +/- 4 vs. 33 +/- 9, p < 0.02). In our community male patients with a diagnosis of coronary artery disease and age less than 50 years showed a higher frequency of the M1- allele at the -75-bp site of the Apo A1 gene. There was a significant increase in the frequency of the M1- allele in patients with unstable angina and no association with risk factors. In the +83-bp polymorphism there was no difference in the allelelic frequencies or the risk factors, except for the HDL cholesterol and total cholesterol where the patients with the allele M2- had lower levels than those homozygous for the M2+.
基因研究已确定载脂蛋白(Apo)A1基因的多态性与高密度脂蛋白胆固醇及载脂蛋白水平相关,并且也有报道称冠状动脉疾病的严重程度与Apo A1 5'-端的多态性之间存在关联。本研究旨在探讨Apo A1基因多态性与早期冠状动脉疾病风险之间的关系。此外,还分析了该多态性与经典危险因素的关联。对总共176例男性患者(平均年龄43±5岁)进行了前瞻性评估,这些患者被诊断为患有不稳定型心绞痛(53例)或心肌梗死(123例)。记录了有关高血压、糖尿病和吸烟的数据。测定了总胆固醇、高密度脂蛋白胆固醇、Apo A1和B以及甘油三酯的水平。从这176例患者和200例对照中获取DNA。为了确定两个多态性位点(-75 bp处的G/A和+83 bp处的C/T)的Apo A1基因型,对DNA进行PCR扩增并用MspI酶切。-75 bp位点罕见等位基因携带者(M1-)的频率在病例组中为0.34,在对照组中为0.24(p<0.05)。心绞痛患者和心肌梗死患者中M1-等位基因的频率分别为0.43(p = 0.009,心绞痛组与对照组相比)和0.30。未发现该多态性与其他心血管危险因素之间存在显著关联。在+83-bp多态性(M2)的罕见等位基因携带者频率方面,心绞痛患者(0.08对0.07)或心肌梗死患者(0.04对0.07)之间未观察到差异,并且未发现该多态性与吸烟、高血压和糖尿病之间存在关联。携带罕见M2-等位基因的患者与未携带该等位基因的患者相比,总胆固醇浓度较低(183±29对223±54,p<0.04),携带M2-的患者中高密度脂蛋白胆固醇也较低(26±4对33±9,p<0.02)。在我们的社区中,诊断为冠状动脉疾病且年龄小于50岁的男性患者在Apo A1基因-75-bp位点的M1-等位基因频率较高。不稳定型心绞痛患者中M1-等位基因频率显著增加,且与危险因素无关。在+83-bp多态性中,等位基因频率或危险因素没有差异,除了高密度脂蛋白胆固醇和总胆固醇,携带M2-等位基因的患者这些指标水平低于M2+纯合子患者。